Trovagene (TROV) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Trovagene (TROV) Misses Q2 EPS by 3c

Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments

August 4, 2016 4:15 PM EDT

SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the second quarter ended June 30, 2016.

"I'm excited to be part of the Trovagene team," said Bill Welch, Chief Executive Officer of Trovagene. "We announced a number of significant clinical study results, publications, and new collaborations with leading comprehensive cancer centers in the second quarter. Our focus remains on commercializing our highly sensitive and quantitative liquid biopsy... More